Cargando…

HBV-Derived Synthetic Long Peptide Can Boost CD4(+) and CD8(+) T-Cell Responses in Chronic HBV Patients Ex Vivo

BACKGROUND: Vaccination with synthetic long peptides (SLP) is a promising new treatment strategy for chronic hepatitis B virus (CHB). SLP can induce broad T-cell responses for all HLA types. Here we investigated the ability of a prototype HBV-core (HBc)-sequence-derived SLP to boost HBV-specific T c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dou, Yingying, van Montfoort, Nadine, van den Bosch, Aniek, de Man, Robert A, Zom, Gijs G, Krebber, Willem-Jan, Melief, Cornelis J M, Buschow, Sonja I, Woltman, Andrea M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853453/ https://www.ncbi.nlm.nih.gov/pubmed/29220492 http://dx.doi.org/10.1093/infdis/jix614

Ejemplares similares

Elevated serum levels of soluble CD14 in HBeAg‐positive chronic HBV patients upon Peginterferon treatment are associated with treatment response
por: Dou, Yingying, et al.
Publicado: (2019)

Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides ex vivo
por: Jansen, Diahann T. S. L., et al.
Publicado: (2023)

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection
por: Zhang, Hong, et al.
Publicado: (2020)

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2018)

Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma
por: de Beijer, Monique T.A., et al.
Publicado: (2022)

Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy
por: Audsley, Jennifer, et al.
Publicado: (2016)

HBV-Specific CD8+ T-Cell Tolerance in the Liver
por: Baudi, Ian, et al.
Publicado: (2021)

Mafosfamide Boosts GMI-HBVac against HBV via Treg Depletion in HBV-Infected Mice
por: Lin, Qin, et al.
Publicado: (2023)

Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection
por: Ferrando-Martinez, Sara, et al.
Publicado: (2021)

Heterogeneity of HBV-Specific CD8(+) T-Cell Failure: Implications for Immunotherapy
por: Heim, Kathrin, et al.
Publicado: (2019)

Increased HBV Coinfection and Decreased IFN-γ-Producing HBV-Specific CD8+ T Cell Numbers During HIV Disease Progression
por: Zhu, Zhiqiang, et al.
Publicado: (2022)

Increased Expression of miR-487b Is Associated With Poor Prognosis and Tumor Progression of HBV-Related Hepatocellular Carcinoma
por: Cao, Xiangang, et al.
Publicado: (2020)

Designing the next‐generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures
por: Jansen, Diahann TSL, et al.
Publicado: (2021)

CCL19 enhances CD8(+) T-cell responses and accelerates HBV clearance
por: Yan, Yan, et al.
Publicado: (2021)

S gene mutations of HBV in children with HBV-associated glomerulonephritis
por: Lu, Hongzhu, et al.
Publicado: (2012)

Understanding MHC Class I Presentation of Viral Antigens by Human Dendritic Cells as a Basis for Rational Design of Therapeutic Vaccines
por: van Montfoort, Nadine, et al.
Publicado: (2014)

Detection of Hepatitis B Virus (HBV) Genomes and HBV Drug Resistant Variants by Deep Sequencing Analysis of HBV Genomes in Immune Cell Subsets of HBV Mono-Infected and/or Human Immunodeficiency Virus Type-1 (HIV-1) and HBV Co-Infected Individuals
por: Lee, Z., et al.
Publicado: (2015)

Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection–Related Hepatocellular Carcinoma
por: Zhao, Li, et al.
Publicado: (2021)

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
por: Li, Ping, et al.
Publicado: (2021)

Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma
por: Fujita, Misuzu, et al.
Publicado: (2022)

High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68(+) Cells during Chronic HBV Infection
por: Said, Elias A., et al.
Publicado: (2016)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

HBV cccDNA: The Stumbling Block for Treatment of HBV Infection
por: Liu, Shousheng, et al.
Publicado: (2019)

Monitoring the emergence of HBV resistance mutations by HBV-RNA pyrosequencing
por: Bottecchia, Marcelle, et al.
Publicado: (2015)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)

Association of CD44 polymorphisms and susceptibility to HBV‐related hepatocellular carcinoma in the Chinese population
por: Deng, Yan, et al.
Publicado: (2019)

Liver-Resident Memory CD8(+) T Cells: Possible Roles in Chronic HBV Infection
por: Han, Ji Won, et al.
Publicado: (2020)

Monocytes from Chronic HBV Patients React In Vitro to HBsAg and TLR by Producing Cytokines Irrespective of Stage of Disease
por: Boltjes, Arjan, et al.
Publicado: (2014)

Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort
por: Maponga, Tongai G., et al.
Publicado: (2020)

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
por: Gozlan, Yael, et al.
Publicado: (2022)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity
por: Yuan, Si-Yu, et al.
Publicado: (2022)

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
por: Tan, Anthony T, et al.
Publicado: (2021)

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
por: Lim, Young-Suk
Publicado: (2023)

Expression of CD39 on FoxP3(+ )T regulatory cells correlates with progression of HBV infection
por: Tang, Yan, et al.
Publicado: (2012)

Monocytic MDSCs homing to thymus contribute to age-related CD8(+) T cell tolerance of HBV
por: Fang, Zhong, et al.
Publicado: (2022)

TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
por: Heim, Kathrin, et al.
Publicado: (2021)

A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population
por: Wu, Wennan, et al.
Publicado: (2023)

Dynamic changes of HBV markers and HBV DNA load in infants born to HBsAg(+) mothers: can positivity of HBsAg or HBV DNA at birth be an indicator for HBV infection of infants?
por: Chen, Tianyan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uh87i3nq8ldgiub28ig9bihisl